CV/COS Webinar: Applications and Future Directions

At Carevive, we believe that data is a powerful tool that can revolutionize cancer care. In this video, we explore the diverse applications of our data and how it can drive better outcomes for patients and clinicians alike.

One crucial application lies in supporting patient-reported outcome (PRO) measure selection for clinical trial planning. Our real-time data from a standard-of-care population offers contemporary insights into FDA-relevant domains. Unlike historical trial data that can quickly become outdated due to rapidly evolving oncology standards, our data ensures up-to-date and relevant measure selection.

Furthermore, our data serves as a bridge between real-world data and clinical trials. With PRO measures similar in domain coverage and assessment frequency, comparing patient experiences on treatment becomes more comparable, enabling apples-to-apples comparisons for efficacy, safety, and tolerability assessments.

The ability to analyze population-level differences and individual time course changes remotely is yet another valuable aspect of our data. This feature proves instrumental in profiling the impact of care management interventions and predicting risk factors.

Recent Episodes

Hospitals across the country are feeling the strain—too many open roles, not enough trained professionals, and a growing gap between what students learn and what the job actually demands on day one. Training is getting more expensive, timelines are stretching, and healthcare leaders are being forced to rethink how new clinicians enter the field….

In this episode of Care Anywhere, host Lea Sims sits down with Nigerian nurse entrepreneur and advocate Obafemi Arowosegbe to discuss leadership, mentorship, and the future of nursing in Africa. While still a nursing student, Obafemi founded the Nightingale Summit, a growing conference designed to empower nursing students and early-career nurses with leadership skills,…

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…